Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003394 | 1.00 | KMT2A (0.45) | KMT2ANR1H2NR1H3TACR3TSHR | |
| SCHEMBL12413231 | 0.84 | NR1H2 (0.49) | KMT2ANR1H2NR1H3TACR3TSHR | |
| SCHEMBL2010329 | 0.77 | HTR2A (0.33) | KMT2ATSHRHPGDALDH1A1LMNA | |
| SCHEMBL1773270 | 0.76 | ADRA2A (0.36) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL1773267 | 0.76 | ADRA2A (0.36) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL2005987 | 0.73 | KMT2A (0.53) | KMT2ANR1H2NR1H3TACR3MEN1 | |
| SCHEMBL6639945 | 0.72 | KMT2A (0.60) | KMT2ANR1H2NR1H3TACR3TSHR | |
| SCHEMBL24495171 | 0.69 | KMT2A (0.45) | KMT2ANR1H2NR1H3TACR3TSHR | |
| SCHEMBL16965479 | 0.69 | TDP1 (0.56) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL16965481 | 0.69 | TDP1 (0.56) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240492-B1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-07-07 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| US-7964739-B2 | Through a stilbene derivative, to a pyrrolidine intermediate, followed by cyclization; asenapine is an antipsychotic agent; industrial scale | N.V. ORGANON (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-2240492-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. Organon (NL) | 2010-10-20 | — | — | EP | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON | 2009-09-10 | — | — | US | disclosed |
| WO-2009087058-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | N.V. ORGANON (NL) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166363-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | KMT2A 1335/4885NR1H2 1244/4885NR1H3 1368/4885 |
| US-20090227803-A1 | PROCESS FOR THE PREPARATION OF ASENAPINE AND INTERMEDIATE PRODUCTS USED IN SAID PROCESS | DHPS, CYP3A5, PNMT | KMT2A 1335/4885NR1H2 1244/4885NR1H3 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.